Post Marketing Surveillance in Japan on Long Term Drug Use of JARDIANCE Tablets in Patients With Type 2 Diabetes Mellitus

Trial Profile

Post Marketing Surveillance in Japan on Long Term Drug Use of JARDIANCE Tablets in Patients With Type 2 Diabetes Mellitus

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs Empagliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 22 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 21 Feb 2017 Planned number of patients changed from 6000 to 8000.
    • 07 Jul 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top